Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

COVID-19 Pneumonia Clinical Trial

Official title:
A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Wuhan) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)

Status Active, not recruiting

Clinical Trial Summary

Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose: COVAX only, 2nd dose: COVAX only; Control Group B (468 subjects): 1st dose: PPV23 only, 2nd dose: IIV4 only. Blood samples will be collected 3 times: before the 1st dose of vaccinatioin; before the 2nd dose of vaccination; 28 days after the 2nd dose of vaccination. The immunogenicity and safety of both experimental and control groups will be analyzed.

Clinical Trial Description

This randomized, parallel, controlled study is designed to evaluate the immunogenicity and safety of simultaneously immunization of COVAX + PPV23 and COVAX + IIV4. 1404 subjects are divided into 3 groups, including 1 experimental group and 2 control groups (control group A and B). Each group includes 468 subjects respectively. Experimental Group (468 subjects) will receive: 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects) will receive: 1st dose: COVAX only, 2nd dose: COVAX only; Control Group B (468 subjects) will receive: 1st dose: PPV23 only, 2nd dose: IIV4 only. Specifically, each group will be divided again. Each 468-subject group is divided again into 2 age-based subgroups: (1) 18-59 years old; (2) ≥60 years old. Each subgroup includes 234 subjects respectively. Blood samples will be collected 3 times: (1) before the 1st dose of vaccinatioin; (2) before the 2nd dose of vaccination; (3) 28 days after the 2nd dose of vaccination. To evaluate the immunogenicity, the investigators will detect and compare the neutralizing antibody levels, the seroconversion rates and antibody geometric mean concentrations. The safety of all groups will be monitored as well. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05079152
Study type	Interventional
Source	China National Biotec Group Company Limited
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	May 6, 2021
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT04901676` - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia	Phase 3
Not yet recruiting	`NCT04534478` - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19	Phase 4
Active, not recruiting	`NCT05002517` - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab	Phase 3
Completed	`NCT05008393` - Efficacy of PJS-539 for Adult Patients With COVID-19.	Phase 2
Completed	`NCT04569877` - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia	Phase 2
Not yet recruiting	`NCT05286255` - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias	Phase 1
Completed	`NCT05035589` - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Completed	`NCT06113432` - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study	N/A
Recruiting	`NCT05042063` - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting	`NCT04615429` - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19	Phase 2
Completed	`NCT05047653` - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting	`NCT05047016` - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY	N/A
Active, not recruiting	`NCT05033847` - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above	Phase 2
Recruiting	`NCT06113757` - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease	N/A
Completed	`NCT05504655` - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting	`NCT05035524` - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19	N/A
Completed	`NCT05065879` - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes	Phase 4
Withdrawn	`NCT04390217` - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia	Phase 2
Withdrawn	`NCT04460105` - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia	Phase 1
Suspended	`NCT04901689` - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation	Phase 3